(Q44628170)

4 December 2017

title

Diagnosis and management of hereditary angioedema: an American approach (English)

1 reference

4 December 2017

main subject

hereditary angioedema

1 reference

Bruce L Zuraw

1

1 reference

4 December 2017

publication date

1 December 2003

1 reference

Transfusion and Apheresis Science

4 December 2017

published in

1 reference

4 December 2017

volume

29

1 reference

4 December 2017

issue

3

1 reference

4 December 2017

page(s)

239-245

1 reference

A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

C1 inhibitor and hereditary angioneurotic edema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Detection of C1 inhibitor mutations in patients with hereditary angioedema.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Detection of active kallikrein in induced blister fluids of hereditary angioedema patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Plasma bradykinin in angio-oedema.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Hereditary Angioedema: the Clinical Syndrome and Its Management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Hereditary angioedema: a broad review for clinicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

HEREDITARY ANGIONEUROTIC EDEMA: TWO GENETIC VARIANTS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Hereditary angioedema with normal C1-inhibitor activity in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Hereditary angio-oedema: treatment with C1 esterase inhibitor concentrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

C1 INH concentrate in the therapy of hereditary angioedema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

C1-inhibitor: an anti-inflammatory reagent with therapeutic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2003.08.008

10.1016/J.TRANSCI.2003.08.008

7 January 2021

Identifiers

DOI

1 reference

4 December 2017

1 reference